Moody's to review Valeant on Medicis deal; Novartis touts new Lucentis data;

 @FiercePharma: Good news for pharma's stop-smoking products: Quitters are more successful with patches, drugs, study finds. More | Follow @FiercePharma

> Valeant Pharmaceuticals ($VRX) nabbed a $2.75 billion bridge load for its Medicis Pharmaceutical buyout as Moody's said it would review the company for a downgrade. Report

> Novartis ($NVS) announced new data affirming the long-term safety and effectiveness of its eye treatment Lucentis. Report

> Mylan's ($MYL) Indian subsidiary was selected to supply HIV-fighting drugs to the country's National AIDS Control Organization. Report

> Suppliers will keep turning out substandard drug ingredients as long as drugmakers continue to buy them, the World Health Organization says. Report

> The U.K. has tapped a new health secretary, Jeremy Hunt, to replace Andrew Lansley, who backed a controversial overhaul of the government health service. Report

Biotech News

 @FierceBiotech: Can a triple-play COPD drug protect GSK from Novartis' QVA149? Story | Follow @FierceBiotech

 @JohnCFierce: Orexigen says it will complete Contrave study enrollment later this year, interim analysis in 2013. Release | Follow @JohnCFierce

> Novartis bets big that canakinumab can conquer a vast cardio market. Article

> Intercept Pharma files for $75M IPO to back PhIII liver drug. News

> Roche spotlights top blockbuster bets as it showcases R&D. Report

> Pfizer wins FDA approval for orphan chronic myelogenous leukemia drug. Story

Medical Device News

 @FierceMedDev: Slow growth ahead for the vascular access device market? Release | Follow @FierceMedDev

 @MarkHFierce: Shire has regulatory approval in Canada for its new diabetic foot ulcer treatment. Item | Follow @MarkHFierce

 @DamianFierce: Roche is betting big on companion diagnostics for its pipeline drugs. Article | Follow @DamianFierce

> Intact Vascular lands $15.5M to market PAD device. Story

> CircuLite's tiny blood pump locks down CE mark. News

Biomarkers News

> Mesothelioma markers predict response to Alimta. Story

> Lab aims to pinpoint PTSD with biomarkers. News

> Merck Serono launches biomarker spinoff. More

> Researchers find new brain cancer target. Article

> 'Traffic light test' could spot liver disease earlier. Item

Drug Delivery News

> Nanoparticles protect heart and cut cancer drug resistance. Article

> Cross-shaped RNA carries drugs to cells. More

> Pulmatrix is breathing relief into COPD. Story

> University snags $2.6M for HIV nanodrug delivery. News

And Finally... Mayo Clinic researchers have formulated an assessment to identify rheumatoid arthritis patients at highest risk of infection. Report

Suggested Articles

The FDA has raised questions about the manufacturing of Glenmark's new molecular entity Ryaltris, a nasal spray for seasonal allergic rhinitis.

Despite unconventional support from President Donald Trump, Johnson & Johnson’s Spravato didn’t win broad backing at the VA.

Months after trial deaths prompted the FDA to halt study enrollment for AbbVie’s Venclexta, the agency will give the drug another shot.